Skip To Main Content
Xuejuan Shen on Muck Rack

Xuejuan Shen

As seen in: The Lancet
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Xuejuan

Contact Xuejuan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The Differences in the Evolutionary Dynamics of MERS and SARS Coronaviruses

|
By Jiameng Liu, Xinyuan Cui, Xuejuan Shen, Yushan Ding
| Preprints.org
This version is not peer-reviewed. Yushan Ding  †,Jiameng Liu  †,Jamal S. M. Sabir  †,Xinyuan Cui,Xuejuan Shen,Nahid H. Hajrah,Mohamed M. M. Ahmed,Meshaal J. Sabir,Onaizan Godian AI- Zogabi,David M. Irwin,Yongyi Shen  * Yushan Ding  †,Jiameng Liu  †,Jamal S. M. Sabir  †,Xinyuan Cui,Xuejuan Shen,Nahid H. Hajrah,Mohamed M. M. Ahmed,Meshaal J. Sabir,Onaizan Godian AI- Zogabi,David M. Irwin,Yongyi Shen  * † These authors contributed equally. This version is not peer-reviewed.
Open in Who Shared Issue with article?

Vaccine against Middle East respiratory syndrome coronavirus

|
By Yongyi Shen, Xuejuan Shen, David M Irwin
| The Lancet Verified
In The Lancet Infectious Diseases, Kayvon Modjarrad and colleagues reported results of the first in-human clinical trial of the GLS-5300 vaccine candidate against Middle East respiratory syndrome (MERS)coronavirus. The vaccine induced both humoral and cellular MERS coronavirus-specific immune responses. These data suggest that GLS-5300 has potential value in protecting humans from MERS coronavirus infections. However, who should be vaccinated?
Open in Who Shared Issue with article?
See all 2 articles